Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
ARAY 
Accuray Incorporated (ARAY)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: ARAY (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
4 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $5.5
1 Year Target Price $5.5
| 3 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -65.75% | Avg. Invested days 27 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/14/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 150.40M USD | Price to earnings Ratio - | 1Y Target Price 5.5 |
Price to earnings Ratio - | 1Y Target Price 5.5 | ||
Volume (30-day avg) 4 | Beta 1.24 | 52 Weeks Range 1.14 - 2.95 | Updated Date 08/14/2025 |
52 Weeks Range 1.14 - 2.95 | Updated Date 08/14/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) - |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-08-13 | When - | Estimate 0.0133 | Actual 0.0055 |
Profitability
Profit Margin 0.15% | Operating Margin (TTM) 3.73% |
Management Effectiveness
Return on Assets (TTM) 1.72% | Return on Equity (TTM) 1.49% |
Valuation
Trailing PE - | Forward PE 94.34 | Enterprise Value 290033942 | Price to Sales(TTM) 0.32 |
Enterprise Value 290033942 | Price to Sales(TTM) 0.32 | ||
Enterprise Value to Revenue 0.62 | Enterprise Value to EBITDA 14.08 | Shares Outstanding 103013000 | Shares Floating 99496507 |
Shares Outstanding 103013000 | Shares Floating 99496507 | ||
Percent Insiders 2.26 | Percent Institutions 64.04 |
Upturn AI SWOT
Accuray Incorporated
Company Overview
History and Background
Accuray Incorporated was founded in 1990. It is a radiation oncology company that develops, manufactures and sells radiotherapy systems for cancer treatment.
Core Business Areas
- Radiotherapy Systems: Development, manufacturing, and sale of radiotherapy systems, primarily the CyberKnife and TomoTherapy platforms. This includes hardware, software, and related services.
- Service and Support: Provides maintenance, training, and support services for installed systems.
Leadership and Structure
Suzanne Winter is the President and CEO. The company has a board of directors and operates with functional departments covering R&D, sales, marketing, manufacturing, and finance.
Top Products and Market Share
Key Offerings
- CyberKnife Robotic Radiosurgery System: A robotic radiosurgery system designed for precise delivery of radiation to tumors throughout the body. Competitors include Varian (VAR) and Elekta (EKTAY). Market share data is not consistently reported but estimated to be within the 20-30% range in its market segment with revenue contributions being substantial.
- TomoTherapy System: A radiation therapy system that integrates imaging and treatment, allowing for precise, image-guided radiation delivery. Primary competitors are Varian (VAR) and Elekta (EKTAY). Market share data is not consistently reported but estimated to be within the 15-25% range in its market segment.
Market Dynamics
Industry Overview
The radiation oncology industry is characterized by technological advancements, increasing cancer incidence, and an aging population. Key trends include hypofractionation and stereotactic body radiation therapy (SBRT).
Positioning
Accuray is positioned as a leader in precision radiation therapy, particularly with its CyberKnife system. Competitive advantages include robotic precision and image guidance.
Total Addressable Market (TAM)
The global radiotherapy market is expected to reach $8.9 billion by 2028. Accuray is positioned to address a portion of this TAM through its CyberKnife and TomoTherapy systems.
Upturn SWOT Analysis
Strengths
- Technological innovation (CyberKnife robotics)
- Precise radiation delivery
- Strong brand recognition in certain segments
- Global presence
Weaknesses
- Smaller market share compared to larger competitors
- Financial performance variability
- Customer concentration
- High service costs
Opportunities
- Expanding applications of SBRT
- Growth in emerging markets
- Strategic partnerships and acquisitions
- Technological advancements in AI and imaging
Threats
- Intense competition from Varian and Elekta
- Pricing pressures
- Regulatory changes
- Technological obsolescence
Competitors and Market Share
Key Competitors
- VAR
- EKTAY
Competitive Landscape
Accuray faces intense competition from larger, more established players like Varian and Elekta. While Accuray's CyberKnife offers unique capabilities, it must continually innovate to maintain its competitive edge.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been inconsistent, with periods of expansion followed by periods of contraction.
Future Projections: Analyst estimates suggest potential for revenue growth driven by new product adoption and expansion in emerging markets.
Recent Initiatives: Focus on product innovation, strategic partnerships, and geographic expansion.
Summary
Accuray is a radiation oncology company with strengths in robotic radiosurgery but faces challenges related to competition and inconsistent financial performance. Its innovative CyberKnife system and TomoTherapy system are key differentiators, but the company needs to improve its profitability and market position. Strategic initiatives focused on new product development and geographic expansion are crucial for future growth. Accuray must be cautious of competitor actions in order to remain competitive in its space.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings
- Analyst reports
- Industry publications
Disclaimers:
The information provided is for informational purposes only and does not constitute investment advice. Market share data is based on estimates and may vary.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Accuray Incorporated
Exchange NASDAQ | Headquaters Madison, WI, United States | ||
IPO Launch date 2007-02-08 | President, CEO & Director Ms. Suzanne Winter M.B.A. | ||
Sector Healthcare | Industry Medical Devices | Full time employees 987 | Website https://www.accuray.com |
Full time employees 987 | Website https://www.accuray.com | ||
Accuray Incorporated designs, develops, manufactures, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the United States, Canada, Latin America, Asia, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, and China. It offers the CyberKnife platform, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate. The company also provides the TomoTherapy platform, including the Radixact System, which allows for integrated radiation treatment planning, delivery, and data management, enabling clinicians to deliver ultra-precise treatments to approximately 50 patients per day; iDMS data management system, a fully integrated treatment planning and data management systems; and Accuray precision treatment planning system, a treatment planning and data management systems. In addition, it offers post-contract customer support, installation, training, and other professional services. The company primarily markets its products directly to customers, including hospitals and stand-alone treatment facilities through its sales organization, as well as to customers through sales agents and group purchasing organizations in the United States; and to customers directly and through distributors and sales agents internationally. Accuray Incorporated was incorporated in 1990 and is headquartered in Madison, Wisconsin.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.